Last reviewed · How we verify
Infective blepharitis
Approved treatments
- Ramycin
Fusidic acid works by inhibiting the function of the bacterial ribosome, preventing the production of essential proteins. - Cortisporin · Pfizer
- Garamycin · Merck & Co.
- Tobi · Novartis
- Cortifoam · Pfizer
- Klaron · Merck & Co.
- Cortone
- Decadron · Generic (originally Merck)
- Vantobra · Pfizer
- Gentamicin · Merck & Co.
- Nebcin · University Hospital, Lille
- Cortisporin · Pfizer
- Cortef · Generic (originally Merck/Upjohn)
- Cortisporin · Pfizer
- Gramoderm · Pfizer
- Cortisol · University of Zurich
- Prelone · Generic (originally Schering)
- prednisolon · Hannover Medical School
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Infective blepharitis patent landscape — cliff calendar, originator estates, attackable patents
- Infective blepharitis treatment landscape brief
- Infective blepharitis treatment updates RSS
Frequently asked questions about Infective blepharitis
What drugs treat Infective blepharitis?
Tracked treatments include Ramycin, Cortisporin, Garamycin, Tobi, Cortifoam, Klaron, Cortone, Decadron.
What is the treatment for Infective blepharitis?
Standard treatment for Infective blepharitis includes Ramycin, Cortisporin, Garamycin, Tobi, Cortifoam. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Infective blepharitis patent cliff · Infective blepharitis CI report
- Treatment: Ramycin
- Treatment: Cortisporin · Pfizer
- Treatment: Garamycin · Merck & Co.
- Treatment: Tobi · Novartis
- Treatment: Cortifoam · Pfizer
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing